Detroit, MI8 Active Studies

Spinal Muscular Atrophy Clinical Trials in Detroit, MI

Find 8 actively recruiting spinal muscular atrophy clinical trials in Detroit, MI. Connect with local research sites and explore new treatment options.

8
Active Trials
8
Sponsors
1,475
Enrolling

Recruiting Spinal Muscular Atrophy Studies in Detroit

RecruitingDetroit, MINCT06074588

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19de...

556 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingDetroit, MINCT04471727

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig w...

232 participants
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
View Study Details
RecruitingDetroit, MINCT06161441

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug...

180 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingDetroit, MINCT06448754

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with spe...

180 participants
AstraZeneca
View Study Details
RecruitingDetroit, MINCT06855771

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion ...

130 participants
Bristol-Myers Squibb
View Study Details
RecruitingDetroit, MINCT06362252

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participan...

123 participants
Daiichi Sankyo
View Study Details
RecruitingDetroit, MINCT05903092

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer

The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, sub...

38 participants
Hirva Mamdani
View Study Details
RecruitingDetroit, MINCT05271292

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (...

36 participants
Chipscreen Biosciences, Ltd.
View Study Details

About Spinal Muscular Atrophy Clinical Trials in Detroit

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 8 spinal muscular atrophy clinical trials recruiting participants in Detroit, MI. These studies are seeking a combined 1,475 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Regeneron Pharmaceuticals and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Detroit — FAQ

Are there spinal muscular atrophy clinical trials in Detroit?

Yes, there are 8 spinal muscular atrophy clinical trials currently recruiting in Detroit, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Detroit?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Detroit research site will contact you about next steps.

Are clinical trials in Detroit free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Detroit studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 8 active trials in Detroit are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov